An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives

• Published in: Expert opinion on drug discovery Vol. 16; no. 7; p. 745
• Main Authors: Su, Ma, Gong, Xingyu, Liu, Feng
• Format: Journal Article
• Language: English
• Published: England 03.07.2021
• Subjects: Drug Discovery; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylases; Humans; Lysine; Neoplasms - drug therapy; multitargeting agents; rational design; Histone deacetylases; isoform selectivity; anti-cancer
• ISSN: 1746-045X
• DOI: 10.1080/17460441.2021.1877656

HDACs catalyze the removal of acetyl groups from the ε-N-acetylated lysine residues of various protein substrates including both histone and nonhistone proteins. Different HDACs have distinct biological functions and are recruited to specific regions of the genome. HDAC inhibitors have attracted much attention in recent decades; indeed, there have been more than thirty HDAC inhibitors investigated in clinic trials with five approvals being achieved. This review covers the emerging approaches for HDAC inhibitor drug discovery from the past five years and includes discussion of structure-based rational design, isoform selectivity, and dual mechanism/multi-targeting. Chemical structures in addition to the in vitro and in vivo inhibiting activity of these compounds have also been discussed. The exact role and biological functions of HDACs is still under investigation with a variety of HDAC inhibitors having been designed and evaluated. HDAC inhibitors have shown promise in treating cancer, AD, metabolic disease, viral infection, and multiple sclerosis, but there is still a lot of room for clinical improvement. In the future, more efforts should be put into (i) HDAC isoform identification (ii) the optimization of selectivity, activity, and pharmacokinetics; and (iii) unconventional approaches for discovering different effective scaffolds and pharmacophores.